October 05 2022

Colca Ms, a leading partner in the supply chain

Both on import, packaging, labeling and distribution

COLCA MS supports AlgoTx in the ACT study, a phase 2 multicenter, randomized clinical trial. The ACT study obtained an FDA IND and clearance from many countries in the European Union

AlgoTx is a French BIOTECH company that develops innovative solutions to relieve patients of complex and difficult to treat pain.

ATX01 inhibits pain messaging caused by peripheral neuropathy and was granted “Fast-Track” designation by FDA for its development in chemotherapy-induced peripheral neuropathy, a frequent side-effect of such cancer treatments.

COLCA MS is a leading partner in the supply of ATX01. COLCA MS manages importation of Drug Product imports to France, performs randomized packaging and labeling services, and ensures the distribution of IMPs* to clinical investigator centers in the European Union and the United States.

Learn more of AlgoTx:

https://algotx.com/

*FDA : Food and Drug Administration

*IMPs : Investigational Medicinal Products

 

chemotherapyfoot pain